As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's Hospital, published in Cell, finds that the brain's resident immune cells, ...
A large-scale genomic study published February 19 in Science has produced the first comprehensive map of the feline ...
Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna ...
Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway ...
Some 17 million Americans are living with genetic mutations tied to an increased risk of getting cancer, Cleveland Clinic researchers warned Monday. And the more than 3,400 mutations identified – ...
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
Triple-negative breast cancer (TNBC), particularly the luminal androgen receptor (LAR) subtype, presents significant ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...
A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the ...
New developments in research could double the survival time of pancreatic cancer patients. Revolution Medicines, a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results